Status:

COMPLETED

Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

Lead Sponsor:

Pfizer

Conditions:

Moderate to Severe Psoriasis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitre...

Eligibility Criteria

Inclusion

  • Active, moderate to severe psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving more than 10% body surface area (BSA) or PASI 10.
  • In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine, and psoralen plus ultraviolet A radiation (PUVA) therapy.
  • Negative urine pregnancy test before the first dose of study drug in all female patients

Exclusion

  • Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
  • Any rheumatologic disease such as rheumatoid arthritis, psoriatic arthritis, gout, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes.
  • Prior exposure to TNF inhibitors including ETN. Prior exposure to efalizumab (Raptiva®) and alefacept (Amevive®) is also prohibited.

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2011

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00936065

Start Date

July 1 2009

End Date

April 1 2011

Last Update

April 9 2012

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Pfizer Investigational Site

Daejeon, Korea, South Korea, 301 721

2

Pfizer Investigational Site

Gyeonggido, Korea, South Korea, 420 717

3

Pfizer Investigational Site

Seoul, Korea, South Korea, 110 744

4

Pfizer Investigational Site

Seoul, Korea, South Korea, 130 702